Tinea capitis in infants in their first 2 years of life: A 12-year study and a review of the literature

Tinea Capitis: A Practical Approach

“…It can be administered as a pulse therapy of 6mg/kg once a week for 6to12 weeks. Serious side effects including hepatoxicity, severe drug hypersensitivity reactions (Stevens-Johnson syndrome), anaphylaxis, torsade de pointes, and prolongation of the QT interval, are rare [23,[41][42][43].…”

“…Treatment in Adults: Drug selection and treatment duration criteria in adult tinea capitis are similar to the ones used for children; however, optimal regimens still unclear. The recommended doses of antifungals in adults are: Terbinafine 250mg per day, Itraconazole 5mg/kg per day (maximum 400mg/day), fluconazole 6mg/kg per day, and ultra-micronized griseofulvin 10 to 15mg/kg per day (maximum 750mg/day) [23,[41][42][43].…”

Management of tinea capitis in children following the withdrawal of griseofulvin from the French market: A fast-track algorithm proposed by the Center of Evidence of the French Society of Dermatology

“…5) No clinical improvement (or even worsening), and initial samples either not taken or negative: in the absence of therapeutic non-compliance, the child should be referred to a tertiary medical center to reassess the diagnosis and take samples for testing of antifungal drug resistance [13]. vii) Infants <10 kg with tinea capitis should be referred to a tertiary medical center because of the lack of sufficient data on which to base recommendations [14,15]. Indeed pharmacokinetic and safety data are lacking in infants; terbinafine is not FDA-approved for infants, cutting the tablets into quarters is not optimal, and, although technically possible, reconstitution of the medication as an oral solution is not widespread; data regarding itraconazole at this age are scant, and an oral suspension of fluconazole may be used in newborns but is not indicated for tinea capitis due to inconstant efficacy [16]; topical drugs are usually not sufficiently efficacious, except for very limited fungal infections.…”